All In MedTech

Device Trial Radar · NCT07650201

Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) Intraocular Lens (IOL) in Adult Participants for Correction of Aphakia Following Cataract Extraction

A Prospective, Multicenter, Open-label, Single-arm Clinical Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) IOL for Correction of Aphakia Following Cataract Extraction

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

340

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Sep 2027

Study completion Sep 2028

Sponsor

Lead sponsor
Kowa Research Institute, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jun 16, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate how well an artificial lens, called an intraocular lens (IOL), performs in adults undergoing cataract surgery. During cataract surgery, the eye's natural lens is removed and replaced with an artificial lens to improve vision. The main goal of the study is to evaluate participants' vision after the IOL is placed in the eye. Approximately one year after surgery, participants' vision will be assessed to determine how clearly they can see. The results of this study will provide additional information about the performance of the IOL in adults undergoing cataract surgery.

Conditions

  • Aphakia, Postcataract

Interventions

  • KI-362-US1 (YP2.2VM)Device

    Injector and one-piece (1P) monofocal IOL

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Achieving a Predefined BCDVA Criterion at Visit 5Time frame: Baseline through Visit 5, approximately Days 330-390.
  2. Proportion of Participants With Selected Ocular Adverse EventsTime frame: Baseline through end of study (up to 15 months)

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Beverly Hills Institute of Ophthalmology

    Beverly Hills, California · Recruiting

  • Icon EyeCare

    Grand Junction, Colorado · Recruiting

  • North Georgia Eye Associates

    Gainesville, Georgia · Recruiting

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.